Opendata, web and dolomites

MyPeBS SIGNED

International Randomized Study Comparing personalized, Risk-Stratified to Standard Breast Cancer Screening In Women Aged 40-70

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MyPeBS" data sheet

The following table provides information about the project.

Coordinator
UNICANCER 

Organization address
address: 101 RUE DE TOLBIAC
city: PARIS
postcode: 75013
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 12˙498˙983 €
 EC max contribution 12˙436˙858 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2025-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNICANCER FR (PARIS) coordinator 2˙915˙337.00
2    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 1˙328˙125.00
3    AZIENDA UNITA SANITARIA LOCALE DI REGGIO EMILIA IT (REGGIO EMILIA) participant 1˙000˙220.00
4    ASSUTA MEDICAL CENTERS LTD IL (TEL AVIV) participant 985˙000.00
5    FONDATION JEAN DAUSSET CENTRE D'ETUDE DU POLYMORPHISME HUMAIN FONDATION FR (PARIS 10) participant 946˙875.00
6    INSTITUT JULES BORDET BE (BRUXELLES) participant 660˙000.00
7    AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO IT (TORINO) participant 593˙400.00
8    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 545˙431.00
9    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) participant 540˙750.00
10    EONIX BE (MONS) participant 520˙000.00
11    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 394˙312.00
12    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) participant 310˙622.00
13    PREDILIFE FR (VILLEJUIF) participant 304˙181.00
14    ISTITUTO SCIENTIFICO ROMAGNOLO PERLO STUDIO E LA CURA DEI TUMORI SRL IT (MELDOLA) participant 250˙000.00
15    ISTITUTO PER LO STUDIO E LA PREVENZIONE E LA RETE ONCOLOGICA IT (FIRENZE) participant 249˙432.00
16    UNIVERSITE PARIS 13 FR (VILLETANEUSE) participant 163˙735.00
17    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 159˙538.00
18    UNIVERSITE LYON 1 CLAUDE BERNARD FR (VILLEURBANNE CEDEX) participant 158˙735.00
19    QUEEN MARY UNIVERSITY OF LONDON UK (LONDON) participant 103˙940.00
20    ASSOCIATION EUROPEENNE DES LIGUES CONTRE LE CANCER ASBL BE (BRUXELLES) participant 86˙450.00
21    INTUITIM BE (EVERE) participant 77˙706.00
22    COLLEGE NATIONAL DES GENERALISTES ENSEIGNANTS FR (MONTREUIL) participant 70˙250.00
23    INDEPENDENT CANCER PATIENTS' VOICE UK (LONDON) participant 25˙000.00
24    THE REGENTS OF THE UNIVERSITY OF CALIFORNIA US (OAKLAND CA) participant 25˙000.00
25    AGENCE NATIONALE DE SANTE PUBLIQUE FR (SAINT MAURICE) participant 12˙500.00
26    FONDATION ARC POUR LA RECHERCHE SUR LE CANCER FR (VILLEJUIF) participant 6˙250.00
27    LOUGHBOROUGH UNIVERSITY UK (LOUGHBOROUGH) participant 4˙066.00
28    IM3D SPA IT (TORINO) participant 0.00

Map

 Project objective

MyPeBS addresses the crucial and timely question of the future of breast cancer screening in Europe. Indeed current standard mammographic screening, with entry stratified by age alone, has recently been largely questioned. Despite a demonstrated mean 20% reduction in breast cancer-specific mortality, together with reduction of late-stage disease in women older than 50, it is associated with potential harms including false positive recalls and over-diagnosis. Individual breast cancer risk estimation, through models including clinical variables, mammographic breast density and more than 100 genetic polymorphisms, now has substantial clinical and scientific bases. Personalized screening strategies, based on individual risk levels, could potentially improve the individual benefit/harms ratio of screening (earlier cancer detection and less intensive treatments in high risk women, less false positives and over-diagnoses in low risk ones), and increase the cost-efficacy for health insurances. MyPEBS will conduct an international randomized phase III trial to validate this hypothesis. It will primarily assess the ability of an individual risk-based screening strategy to be non-inferior, and possibly superior, to the standard of care screening, in reducing the cumulative incidence of stage II breast cancers. The trial, conducted in 5 countries (France, Italy, UK, Belgium and Israel) will include 85000 European women aged 40-70, all followed for 4 years. MyPEBS will also evaluate if an individual risk-based screening strategy, compared with the standard, reduces screening-related harms (unnecessary biopsies, overdiagnoses) in low-risk women, is overall at least as cost-effective as well as more accepted by women resulting in a larger screening coverage. After analyses of all components, the final objective of MyPEBS is to deliver recommendations for the best future breast cancer screening strategy in Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYPEBS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYPEBS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More